News from mabvax therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 07, 2015, 08:00 ET

MabVax Therapeutics Appoints Tom Varvaro to its Board of Directors

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"), a clinical-stage cancer immunotherapy company, announced today that Tom...

Apr 06, 2015, 09:36 ET

MabVax Therapeutics Announces Closing of Financing

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"), a clinical-stage cancer immunotherapy company, is pleased to...

Mar 26, 2015, 08:00 ET

MabVax Therapeutics Enters Into Exchange Agreements To Issue Common Stock and Series D Preferred Stock Eliminating Series A-1 and B Convertible Preferred and Related Warrants

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), acancer diagnostic and immunotherapy company, today announced that it had successfully...

Mar 03, 2015, 08:00 ET

MabVax Therapeutics to Present at the 27th Annual Roth Conference

 MabVax Therapeutics (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that David Hansen, the Company's President...

Feb 04, 2015, 08:00 ET

MabVax Therapeutics Selected To Present at 2015 BIO CEO & Investor Conference

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that it has been selected to make...

Dec 11, 2014, 08:30 ET

MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected...

Nov 19, 2014, 14:00 ET

MabVax Therapeutics And Memorial Sloan-Kettering Cancer Center Report on Potential Use of Dual-Labeled Antibody To Detect and Guide Surgical Removal of Pancreatic Cancer

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company in conjunction with the Department of Radiology...

Oct 23, 2014, 08:00 ET

MabVax Therapeutics Launches Online Corporate Communication Channels and New Website

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate...

Oct 21, 2014, 09:00 ET

MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated...

Oct 10, 2014, 08:00 ET

MabVax Therapeutics Announces Stock Ticker Symbol Change to MBVX

 MabVax Therapeutics Holdings, Inc. ("MabVax"), a clinical stage oncology drug development company, announced today that FINRA has approved a...

Sep 25, 2014, 09:00 ET

MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma

 MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and...

Sep 10, 2014, 09:00 ET

MabVax Therapeutics Enters Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Development of Anti-Cancer Therapeutics

 MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, announced today it has entered into...

Sep 09, 2014, 09:00 ET

MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse Stock Split Resulting From Merger With Telik

MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders...

Jul 09, 2014, 09:30 ET

MabVax Therapeutics Raises $3 Million In Common Stock Financing And An Additional $1.5 Million Upon Exercise Of Series C-1 Warrants

 MabVax Therapeutics, Inc., a privately held cancer immunotherapy company has closed a $3 Million common stock financing.  MabVax entered...

May 12, 2014, 16:30 ET

MabVax Therapeutics And Telik Sign Definitive Merger Agreement

 MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug...

Sep 24, 2013, 07:00 ET

MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of innovative vaccine and antibody...

Dec 18, 2012, 07:00 ET

MabVax Therapeutics Receives SBIR Program Award From The National Cancer Institute To Manufacture Clinical Supplies For Phase 2 Neuroblastoma Trial

MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies...

Nov 20, 2012, 07:00 ET

MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to...

Apr 11, 2011, 07:00 ET

MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies...

Aug 17, 2010, 08:00 ET

MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies...